Latest Carcinoma Stories

The identification of an oncogene (called BRF2) specific to lung squamous cell carcinoma suggests that genetic activation of this oncogene could be used as an identification marker for this type of lung cancer. Furthermore, this oncogene may provide a new target for therapeutics for lung squamous cell carcinoma. These findings come from a study by William Lockwood and colleagues from the BC Cancer Agency's Research Centre in Vancouver, Canada, and are reported in this week's PLoS...

The spread of cancer cells in the tongue may be reduced if a gene that regulates cancer cell migration can be controlled, according to new research at the University of Illinois at Chicago.Oral cancer is an under-treated and poorly understood disease, says Xiaofeng "Charles" Zhou, assistant professor in the UIC Center for Molecular Biology of Oral Diseases and lead researcher of the study.More than 90 percent of oral cancers are squamous cell carcinomas that normally start on the...

Research: Genus Beta human papillomaviruses and incidence of basal cell and squamous cell carcinomas of the skin: Population-based case-control studyHPV infection heightens the risk of developing certain skin cancers and is worsened if people are taking immunosuppression drugs, according to a new study published on bmj.com today.An international team of researchers found that people with several types of human papillomaviruses (HPVs) were more than one and a half times as likely to develop...

WALTHAM, Mass., June 29 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, through 2019, robust 4.1 percent annual growth in the renal cell carcinoma drug market will be driven primarily by the uptake of GlaxoSmithKline's Votrient/Patorma, the launches of premium-priced emerging therapies and an increase in diagnosed incidence and treatment rates. The Pharmacor 2010 findings from the topic...

Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant digestive tumor with a very poor prognosis. Hypoxia-inducible transcription factor-1α (HIF-1α) is involved in malignant progression in many solid tumors, including PDAC, upregulation of HIF-1α accelerates PDAC progression, but the exact regulatory mechanisms of HIF-1αin PDAC has not been unequivocally addressed. Recently, an increasing number of studies reported that toll-like receptors (TLRs) were upregulated in...

CHICAGO, June 4 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the first results from its collaboration with Pfizer Oncology to study early-stage renal cell carcinoma prognosis, which demonstrated a strong correlation between gene expression and recurrence risk in this patient population. The study, which will be presented in an oral presentation tomorrow (8 - 9:30 a.m. CT) at the ASCO annual meeting in Chicago, could lead to the development of a multi-gene...

SAN DIEGO, June 2 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced that it will report new data on its proprietary oncology diagnostic platform, a novel technology that forms the basis of the Company's recently announced collaboration with Bayer Schering Pharma AG. The new data will be highlighted in three separate presentations at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago: Analysis of...

Hepatocellular carcinoma (HCC) is an aggressive tumor with poor long-term prognosis. The reported 5-year recurrence rate ranges from 75% to 100%. Therefore, extrahepatic metastasis of HCC is uncommon due to the highly malignant nature of the primary tumor. However, with advances in different treatment modalities for HCC, the incidence of extrahepatic metastasis appears to be increasing. Nevertheless, most recurrences occur relatively early after the initial diagnosis and treatment.A research...

Today, during the 39th Annual Meeting of the American Association for Dental Research, convening at the Walter E. Washington Convention Center in Washington, DC, lead researcher M. Tong, The Ohio State University, will present a poster of a study titled "Epithelial-to-Endothelial Transition: An Epithelial Phenotypic Modulation Facilitating Oral-Squamous-Cell Carcinoma Progression." Tong and a team of researchers have reported that oral squamous cell carcinoma (OSCC) cells...

Contrary to previous hypotheses, the use of non-steroidal anti-inflammatory drugs does not appear associated with risk of squamous cell skin cancer, according to a report posted online today that will appear in the April print issue of Archives of Dermatology, one of the JAMA/Archives journals.Non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin, ibuprofen and celecoxib reduce pain and inflammation by blocking an enzyme involved in producing inflammatory compounds, according to...